Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovaBridge BiosciencesNBP · Entity 6324 | General Counsel | July 08, 2026 | July 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovaBridge Biosciences
Report date July 08, 2026 · Filed July 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| 2025 Employee Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.93 · Expires 2036-07-08 | Direct | 254,780 |
Reported balance
After 2026-07-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-08 · Grant · Acquired 254,780 · Balance 254,780 F1: Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS"). F2: The option vests and becomes exercisable over five years, with 40% vesting on the second anniversary of February 1, 2026 and the balance vesting in three equal annual installments thereafter. F3: The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS").
F2: The option vests and becomes exercisable over five years, with 40% vesting on the second anniversary of February 1, 2026 and the balance vesting in three equal annual installments thereafter.
F3: The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 08, 2026 Filed Jul 10, 2026 21:00 UTC | NovaBridge Biosciences NBP · Entity 6324 | Grant2025 Employee Share Option (right to buy) · Derivative | 254,780 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0002114156-26-000003 · form4-07102026_050707.xml · derivative · entry 1 Lin Liwei Lorraine · CIK 0002114156 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 254,780 Underlying: Ordinary Shares · 254,780 shares Expires 2036-07-08 F1 · derivative.exercise_price: Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS"). F1 · shares: Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS"). F2 · derivative.exercise_date: The option vests and becomes exercisable over five years, with 40% vesting on the second anniversary of February 1, 2026 and the balance vesting in three equal annual installments thereafter. F3 · derivative.underlying: The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F1 · derivative.underlying_shares: Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS"). F1 · balance_after: Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.